Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    0(0%)

    Phase Distribution

    Phase 3
    1
    50%
    Phase 2
    1
    50%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Active(1)
    Other(1)

    Detailed Status

    Not yet recruiting1
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    N/A
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    not_yet_recruiting150%
    unknown150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    not_yet_recruitingphase_3

    Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS

    NCT07877597
    unknownphase_2

    Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

    NCT05588297

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT07877597Phase 3

    Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS

    Not Yet Recruiting
    NCT05588297Phase 2

    Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

    Unknown

    All 2 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    2